Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: A phase II clinical trial

Clinical Cancer Research

Volumn 13, Issue 22, 2007, Pages 6696-6702

  Iten, Fabienne ^a   Müller, Beat ^a   Schindler, Christian ^b   Rochlitz, Christoph ^a   Oertli, Daniel ^a   Mäcke, Helmut R ^a   Müller Brand, Jan ^a   Walter, Martin A ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; YTTRIUM 90; 90Y OCTREOTIDE, DOTA TYR(3); 90Y-OCTREOTIDE, DOTA-TYR(3)-; DRUG DERIVATIVE; OCTREOTIDE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HAZARD RATIO; HEMATOLOGIC DISEASE; HUMAN; LONG TERM CARE; MALE; METASTASIS; MULTIPLE REGRESSION; NEPHROTOXICITY; PRIORITY JOURNAL; RADIATION SAFETY; STATISTICAL SIGNIFICANCE; THYROID MEDULLARY CARCINOMA; THYROID SCINTISCANNING; TREATMENT RESPONSE; CLINICAL PROTOCOL; CLINICAL TRIAL; MEDULLARY CARCINOMA; MIDDLE AGED; MORTALITY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; SURVIVAL; THYROID TUMOR;

ADULT; AGED; CARCINOMA, MEDULLARY; CLINICAL PROTOCOLS; FEMALE; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; RADIOPHARMACEUTICALS; SURVIVAL ANALYSIS; THYROID NEOPLASMS;

EID: 36749090076     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0935     Document Type: Article

References (20)

1. Vini L, Harmer C. Management of thyroid cancer. Lancet Oncol 2002;3:407-14.
2. Vitale G, Caraglia M, Ciccarelli A, Lupoli G, Abbruzzese A, Tagliaferri P. Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer 2001;91:1797-808.
3. Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol (Oxf) 2004;61:299-310.
4. Chatal JF, Campion L, Kraeber-Bodere F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 2006;24:1705-11.
5. Kaltsas G, Rockall A, Papadogias D, Reznek R, Grossman AB. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol 2004;151:15-27.
6. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998;351:417-8.
7. 90Y-DOTA]-D-Phe1-3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001;12:941-5.
8. Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002;43:610-6.
9. Bodei L, Cremonesi M, Grana C, et al. Receptor radionuclide therapy with 90Y-[DOTA]0-3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004;31:1038-46.
10. Krenning EP, Bakker WH, Breeman WA, et al. Localisation of endocrine-related tumours with radio-iodinated analogue of somatostatin. Lancet 1989;1:242-4.
11. Waldherr C, Schumacher T, Pless M, et al. Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using. Nucl Med Commun 2001;22:673-8.
12. Bodei L, Handkiewicz-Junak D, Grana C, et al. Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas. Cancer Biother Radiopharm 2004;19:65-71.
13. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
14. Gatta G, Ciccolallo L, Kunkler I, et al. Survival from rare cancer in adults: a population-based study. Lancet Oncol 2006;7:132-40.
15. Husband JE, Schwartz LH, Spencer J, et al. Evaluation of the response to treatment of solid tumours - a consensus statement of the International Cancer Imaging Society. Br J Cancer 2004;90:2256-60.
16. Engelbach M, Gorges R, Forst T, et al. Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements. J Clin Endocrinol Metab 2000;85:1890-4.
17. Gronlund B, Hogdall C, Hilden J, Engelholm SA, Hogdall EV, Hansen HH. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J Clin Oncol 2004;22:4051-8.
18. Barbet J, Campion L, Kraeber-Bodere F, Chatal JF. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2005;90:6077-84.
19. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,-Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754-62.
20. Behe M, Behr TM. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Biopolymers 2002;66:399-418.